Allogeneic hematopoietic stem cell transplantation for poor-risk CLL: dissecting immune-modulating strategies for disease eradication and treatment of relapse - PubMed

Affiliations

• PMID: 26146810
• DOI: 10.1038/bmt.2015.150

Allogeneic hematopoietic stem cell transplantation for poor-risk CLL: dissecting immune-modulating strategies for disease eradication and treatment of relapse

M Hahn et al. Bone Marrow Transplant. 2015 Oct.

Abstract

To elucidate factors contributing to the effectiveness of allogeneic hematopoietic stem cell transplantation (alloHCT) in high-risk CLL, immune interventions, GvHD and clinical outcome of 77 consecutive patients allografted for CLL were analyzed. Immune modulation (immunosuppression tapering, rituximab-augmented donor lymphocyte infusions) was guided by minimal residual disease (MRD) monitoring and commenced at a median of 91 (22-273) days after alloHCT, resulting in a probability of being event free and MRD-negative 1 year after transplant of 57% (84% in those encountering chronic GvHD). Patients who were event free and MRD-negative at the 12-month landmark had a 4-year PFS of 77% and largely remained durably MRD-negative if MRD clearance had occurred subsequent to immune modulation. Three-year overall survival, PFS, relapse incidence and non-relapse mortality of all 77 patients were 69, 57, 26 and 24%, respectively. Survival was not affected by EBMT risk category but by active disease at alloHCT, which could not be overcome by intensification of conditioning. Twenty-three patients who experienced relapse post alloHCT had a survival of 56% at 2 years after CLL recurrence. In conclusion, MRD-guided immune modulation after alloHCT for high-risk CLL can provide durable MRD clearance in more than half of the patients.

Similar articles

• Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia.

  Richardson SE, Khan I, Rawstron A, Sudak J, Edwards N, Verfuerth S, Fielding AK, Goldstone A, Kottaridis P, Morris E, Benjamin R, Peggs KS, Thomson KJ, Vandenberghe E, Mackinnon S, Chakraverty R. Richardson SE, et al. Br J Haematol. 2013 Mar;160(5):640-8. doi: 10.1111/bjh.12197. Epub 2013 Jan 7. Br J Haematol. 2013. PMID: 23293871

• Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation.

  Pérez-Simón JA, Caballero D, Diez-Campelo M, Lopez-Pérez R, Mateos G, Cañizo C, Vazquez L, Vidriales B, Mateos MV, Gonzalez M, San Miguel JF. Pérez-Simón JA, et al. Leukemia. 2002 Aug;16(8):1423-31. doi: 10.1038/sj.leu.2402550. Leukemia. 2002. PMID: 12145680 Review.

• Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.

  Schetelig J, Thiede C, Bornhauser M, Schwerdtfeger R, Kiehl M, Beyer J, Sayer HG, Kroger N, Hensel M, Scheffold C, Held TK, Hoffken K, Ho AD, Kienast J, Neubauer A, Zander AR, Fauser AA, Ehninger G, Siegert W; Cooperative German Transplant Study Group. Schetelig J, et al. J Clin Oncol. 2003 Jul 15;21(14):2747-53. doi: 10.1200/JCO.2003.12.011. J Clin Oncol. 2003. PMID: 12860954

• Baseline Characteristics Predicting Very Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Patients With High Cytogenetic Risk Chronic Lymphocytic Leukemia - A Retrospective Analysis From the Chronic Malignancies Working Party of the EBMT.

  van Gelder M, Ziagkos D, de Wreede L, van Biezen A, Dreger P, Gramatzki M, Stelljes M, Andersen NS, Schaap N, Vitek A, Beelen D, Lindström V, Finke J, Passweg J, Eder M, Machaczka M, Delgado J, Krüger W, Raida L, Socié G, Jindra P, Afanasyev B, Wagner E, Chalandon Y, Henseler A, Schoenland S, Kröger N, Schetelig J; CLL Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. van Gelder M, et al. Clin Lymphoma Myeloma Leuk. 2017 Oct;17(10):667-675.e2. doi: 10.1016/j.clml.2017.06.007. Epub 2017 Jun 17. Clin Lymphoma Myeloma Leuk. 2017. PMID: 28694085

• Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning.

  Dreger P, Brand R, Hansz J, Milligan D, Corradini P, Finke J, Deliliers GL, Martino R, Russell N, Van Biezen A, Michallet M, Niederwieser D; Chronic Leukemia Working Party of the EBMT. Dreger P, et al. Leukemia. 2003 May;17(5):841-8. doi: 10.1038/sj.leu.2402905. Leukemia. 2003. PMID: 12750695 Review.

Cited by

• The impact of allogeneic hematopoietic cell transplantation on the mortality of poor-risk non-Hodgkin lymphoma: an intent-to-transplant analysis.

  Selberg L, Stadtherr P, Dietrich S, Tran TH, Luft T, Hegenbart U, Bondong A, Meissner J, Liebers N, Schmitt M, Ho AD, Müller-Tidow C, Dreger P. Selberg L, et al. Bone Marrow Transplant. 2021 Jan;56(1):30-37. doi: 10.1038/s41409-020-0976-4. Epub 2020 Jun 18. Bone Marrow Transplant. 2021. PMID: 32555407

• Efficacy of minimal residual disease driven immune-intervention after allogeneic hematopoietic stem cell transplantation for high-risk chronic lymphocytic leukemia: results of a prospective multicenter trial.

  Tournilhac O, Le Garff-Tavernier M, Nguyen Quoc S, Forcade E, Chevallier P, Legrand-Izadifar F, Laurent Damaj G, Michonneau D, Tomowiak C, Borel C, Orvain C, Turlure P, Redjou R, Guillerm G, Vincent L, Simand C, Lemal R, Quiney C, Combes P, Pereira B, Calvet L, Cabrespine A, Bay JO, Leblond V, Dhédin N, Organization Filo FIL, De Moelle Et de Thérapie Cellulaire Sfgm-Tc SFG. Tournilhac O, et al. Haematologica. 2021 Jul 1;106(7):1867-1875. doi: 10.3324/haematol.2019.239566. Haematologica. 2021. PMID: 32527951 Free PMC article.

• Experience with ibrutinib for first-line use in patients with chronic lymphocytic leukemia.

  Itchaki G, Brown JR. Itchaki G, et al. Ther Adv Hematol. 2018 Jan;9(1):3-19. doi: 10.1177/2040620717741861. Epub 2017 Nov 28. Ther Adv Hematol. 2018. PMID: 29317997 Free PMC article. Review.

• Transplantation in CLL: what we can learn from a dinosaur.

  Dreger P, Montserrat E. Dreger P, et al. Bone Marrow Transplant. 2016 Jun;51(6):765-6. doi: 10.1038/bmt.2016.27. Epub 2016 Feb 29. Bone Marrow Transplant. 2016. PMID: 26926227 No abstract available.

• Ibrutinib as a bridge to transplant in high-risk chronic lymphocytic leukemia: A case report and review of the literature.

  Annalisa A, Simona B, Lara P, Elena T, Filippo MC, Angela R, Luca Z, Daniele V. Annalisa A, et al. Leuk Res Rep. 2017 Nov 15;8:21-23. doi: 10.1016/j.lrr.2017.11.001. eCollection 2017. Leuk Res Rep. 2017. PMID: 29234595 Free PMC article.

References

MeSH terms

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group
  • Ovid Technologies, Inc.